Patents by Inventor Scott Lefler
Scott Lefler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10772837Abstract: The present invention provides modified release pharmaceutical compositions, and methods for administering the compositions to a user, including humans. The composition may contain a combination of ingredients in proportions calculated to achieve therapeutic effect, including at least the following ingredients: one or more natural or synthetic cannabinoids, one or more release modifying agent(s), and one or more pharmaceutically acceptable excipient(s). The composition may be in a multi-layered solid dosage form to provide fast, controlled and also sustained release of specific ingredients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. More specifically, the invention may control drug release in accordance with the therapeutic purpose and pharmacological properties of active substances.Type: GrantFiled: March 15, 2018Date of Patent: September 15, 2020Assignee: CannTab Therapeutics, LtdInventors: Robert Scott Lefler, Jeff Renwick, Joshi Laxminaraya
-
Publication number: 20180263913Abstract: The present invention provides modified release pharmaceutical compositions, and methods for administering the compositions to a user, including humans. The composition may contain a combination of ingredients in proportions calculated to achieve therapeutic effect, including at least the following ingredients: one or more natural or synthetic cannabinoids, one or more release modifying agent(s), and one or more pharmaceutically acceptable excipient(s). The composition may be in a multi-layered solid dosage form to provide fast, controlled and also sustained release of specific ingredients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. More specifically, the invention may control drug release in accordance with the therapeutic purpose and pharmacological properties of active substances.Type: ApplicationFiled: March 15, 2018Publication date: September 20, 2018Inventors: Robert Scott Lefler, Jeff Renwick
-
Publication number: 20180250262Abstract: The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modified release pharmaceutical compositions comprising delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), and a process for preparation thereof. The present invention also provides large scale batches of modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: February 15, 2018Publication date: September 6, 2018Inventors: Jeff Renwick, Robert Scott Lefler
-
Publication number: 20180214412Abstract: The present invention relates to immediate release pharmaceutical compositions comprising one or more natural or synthetic cannabinoids, and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to immediate release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof.Type: ApplicationFiled: January 23, 2018Publication date: August 2, 2018Inventors: Jeff Renwick, Robert Scott Lefler
-
Publication number: 20180085308Abstract: The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. The present invention also provides large scale batches of modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: September 27, 2017Publication date: March 29, 2018Inventors: Jeff Renwick, Robert Scott Lefler
-
Patent number: 7344851Abstract: Prenylating enzymes are involved in modifying oncoproteins, such as RAS, so that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. ?-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be designed to enhance affinity and/or specificity for a particular protein substrate.Type: GrantFiled: October 11, 2005Date of Patent: March 18, 2008Assignee: Arizona Biomedical Research CommissionInventors: Seth D. Rose, Steven R. Ottersberg, Karl J. Okolotowicz, Dale E. Robinson, Rosemarie F. Hartman, Scott Lefler
-
Publication number: 20060111329Abstract: Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.Type: ApplicationFiled: January 23, 2006Publication date: May 25, 2006Applicant: ARIZONA BIOMEDICAL RESEARCH COMMISSIONInventors: Seth Rose, Scott Lefler, Steven Ottersberg, Ann Kim, Karl Okolotowicz, Rosemarie Hartman
-
Patent number: 7012097Abstract: Prenylating enzymes are involved in modifying oncoproteins, such as RAS, so that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. ?-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be designed to enhance affinity and/or specificity for a particular protein substrate.Type: GrantFiled: May 14, 2003Date of Patent: March 14, 2006Assignee: The Arizona Disease Control Research CommissionInventors: Seth D. Rose, Steven R. Ottersberg, Karl J. Okolotowicz, Dale E. Robinson, Rosemarie Hartman, Scott Lefler
-
Publication number: 20060030624Abstract: Prenylating enzymes are involved in modifying oncoproteins, such as RAS, so that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. ?-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be designed to enhance affinity and/or specificity for a particular protein substrate.Type: ApplicationFiled: October 11, 2005Publication date: February 9, 2006Applicant: Arizona Disease Control Research CommissionInventors: Seth Rose, Steven Ottersberg, Karl Okolotowicz, Dale Robinson, Rosemarie Hartman, Scott Lefler
-
Publication number: 20030219847Abstract: Prenylating enzymes are involved in modifying oncoproteins, such as RAS, so that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. &agr;-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be designed to enhance affinity and/or specificity for a particular protein substrate.Type: ApplicationFiled: May 14, 2003Publication date: November 27, 2003Applicant: The Arizona Disease Control Research CommissionInventors: Seth D. Rose, Steven R. Ottersberg, Karl J. Okolotowicz, Dale E. Robinson, Rosemarie Hartman, Scott Lefler
-
Patent number: 6576436Abstract: Prenylating enzymes are involved in modifying oncoproteins, such as RAS, so that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. &agr;-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be designed to enhance affinity and/or specificity for a particular protein substrate.Type: GrantFiled: December 9, 1999Date of Patent: June 10, 2003Assignee: The Arizona Disease Control Research CommissionInventors: Seth D. Rose, Steven R. Ottersberg, Karl J. Okolotowicz, Dale E. Robinson, Rosemarie Hartman, Scott Lefler